Revolutionary Liraglutide Drug Cuts Migraine Days by 50%: New Study Reveals

Migraines are a common neurological condition affecting roughly 14.7% of people worldwide, often leading to significant disability and diminished life quality.

Despite numerous available treatments, many individuals still suffer from frequent and unresponsive migraine attacks.

This recent research aimed to test whether liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), could serve as an effective supplemental treatment for those with chronic or high-frequency migraines who have not found relief with at least two other preventive measures.

The study was conducted in Naples, Italy, from January to July 2024.

It included 31 obese adults, each with a body mass index (BMI) over 30, who experienced chronic or high-frequency episodic migraines (eight or more headache days per month) and were unresponsive to at least two preventive treatments, including traditional care and anti-CGRP drugs.

Participants showing signs of idiopathic intracranial hypertension, like papilledema or sixth nerve palsy, were excluded to focus solely on migraines without explicit intracranial hypertension.

Participants were administered daily subcutaneous injections of liraglutide, beginning with 0.6 milligrams in the first week, increasing to 1.2 mg thereafter, while continuing their existing preventive treatments.

Over the course of 12 weeks, participants maintained headache diaries to track their monthly headache days (MHDs) and completed the Migraine Disability Assessment (MIDAS) to measure migraine-related disability.

BMI measurements were taken at the start and end of the study to monitor weight changes.

After 12 weeks, the average monthly headache days dropped from 19.8 to 10.7, reflecting a significant reduction of 9.1 days. This improvement was both statistically significant and clinically meaningful.

Nearly half of the participants (48%) saw at least a 50% reduction in headache frequency, with 23% experiencing a 75% or greater reduction. One individual reported complete cessation of headaches.

The MIDAS scores also significantly decreased from 60.4 to 28.6, indicating significant improvements in daily functioning.

The slight decrease in BMI from 34.0 to 33.9 was not statistically significant, confirming that the reduction in headache frequency was independent of weight loss.

Age, sex, and concurrent medications did not affect the treatment outcome, highlighting the broad applicability of liraglutide’s benefits for migraine sufferers.

The side effects were mild and mostly gastrointestinal, such as nausea and constipation, affecting 42% of participants. No participants discontinued treatment due to these side effects, which resolved on their own.

This study provides initial clinical evidence that liraglutide can effectively reduce migraine frequency and disability in patients with obesity and refractory migraine, likely through mechanisms involving intracranial pressure regulation and CGRP modulation, rather than solely through weight loss.

This opens up a new potential therapeutic direction that differs from current migraine preventives, which primarily focus on blocking the effects of CGRP rather than preventing its release.

However, the study’s open-label design, small sample size, absence of a control group, and short follow-up period are notable limitations.

The underlying theory for this research is supported by emerging evidence that links increased intracranial pressure (ICP) with migraine mechanisms.

Chronic migraine and idiopathic intracranial hypertension without papilledema (IIHWOP) share several clinical features and risk factors, such as obesity and being female. These conditions are also associated with elevated levels of CGRP, a molecule integral to migraine pain pathways.

Notably, common migraine preventatives like topiramate are known to reduce ICP, suggesting that managing brain pressure could be an effective migraine treatment approach.

In animal studies, GLP-1RAs like liraglutide have been shown to lower ICP by suppressing activity in the choroid plexus of an enzyme called the sodium-potassium pump, which is responsible for cerebrospinal fluid secretion. This action helps reduce fluid buildup and pressure inside the skull.

Moreover, these drugs have been shown to decrease CGRP expression and reduce central nervous system sensitization related to migraine.

These encouraging preclinical results prompted researchers to investigate the effects of liraglutide in a clinical setting for migraine sufferers.

However, Peter Soh, MD, MPH, medical director at Soh Headache Center, LLC, who was not involved in the study, pointed out that the exact mechanisms by which GLP-1RAs reduce migraine frequency remain unclear, especially since variables like intracranial pressure were not directly measured in the study population.

“Without additional data, it’s somewhat premature to pinpoint a specific mechanism of action in this context,” he explained to Healthline.

Liraglutide may potentially become an important part of the migraine treatment toolkit, especially for those with hard-to-treat cases, offering new hopes for more effective and specialized relief.

However, before liraglutide can be widely recommended as a treatment for migraines, more rigorous studies and clinical trials are necessary.

Stewart Parnacott, PhD, CRNA, MBA, chief clinical officer at Ready Wellness and author of “Too Young to Feel This Old,” emphasized the need for more conclusive research. Parnacott, who did not participate in the study, cautioned, “We still need to understand how long the benefits last and whether similar results can be seen with other GLP-1 drugs like semaglutide.”

“And I’m not suggesting anyone start using Saxenda just to treat their migraines—at least not yet,” he added during his conversation with Healthline.

For those experiencing frequent migraines, finding effective treatments can be highly individual.

Soh advises consulting with a healthcare provider or a headache specialist trained in this field to tailor your treatment strategy. This approach may include evaluating your lifestyle habits and using a headache journal to monitor your response to different therapies.

“Don’t underestimate the impact of diet, sleep, stress, hydration, hormones, and fluctuations in blood sugar,” Parnacott noted. “I’ve seen patients reduce their migraine days by half simply by making minor adjustments they didn’t think would make a difference.”

Highlighting the complex interactions between the gut, brain, and metabolism, Parnacott emphasized that treating migraines is not just about one single medication. “You never know what piece of the puzzle might change everything,” he concluded.